1
|
Margalef NM, Castillo C, Mosteiro M, Martinez JP, PAdrol I, Aguilar S, Villacampa MM, Rodriguez JR, Losa F, Vega AT, Soler G, Castany R, Capdevila F, Gil-Martin M, Cuadra C, Elez E, Garralda E, Salazar R, Dienstmann R, Santos C. 477P Genomically-matched therapy in refractory CRC according to ESCAT. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
2
|
Soler G, Legido R, Perez X, Martinez-Villacampa M, Santos C, Losa F, Ruffinelli J, Mulet N, Teule A, Castany R, Gallego R, Carbonell M, Manzana A, Rios A, Saldaña J, Salazar R. 513P Prospective evaluation of the G8 screening tool for predicting survival in elderly patients with colon cancer. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
3
|
Torrente-Segarra V, Salman-Monte TC, Rúa-Figueroa Í, Del Campo V, López-Longo FJ, Galindo-Izquierdo M, Calvo-Alén J, Olivé-Marqués A, Mouriño-Rodríguez C, Horcada L, Bohórquez C, Montilla C, Salgado E, Díez-Álvarez E, Blanco R, Andreu JL, Fernández-Berrizbeitia O, Expósito L, Gantes M, Hernández-Cruz B, Pecondón-Español Á, Lozano-Rivas N, Bonilla G, Lois Iglesias A, Rubio-Muñoz P, Ovalles J, Tomero E, Boteanu A, Narvaez J, Freire M, Vela P, Quevedo-Vila V, Juan Mas A, Muñoz-Fernández S, Raya E, Moreno M, Velloso-Feijoo ML, Soler G, Vázquez-Rodríguez TR, Pego-Reigosa JM. Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER). Semin Arthritis Rheum 2020; 50:657-662. [PMID: 32505871 DOI: 10.1016/j.semarthrit.2020.05.016] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2020] [Revised: 05/09/2020] [Accepted: 05/11/2020] [Indexed: 10/24/2022]
Abstract
OBJECTIVE To assess the incidence of serious infection (SI) and associated factors in a large juvenile-onset systemic lupus erythematosus (jSLE) retrospective cohort. METHODS All patients in the Spanish Rheumatology Society Lupus Registry (RELESSER) who meet ≥4 ACR-97 SLE criteria and disease onset <18 years old (jSLE), were retrospectively investigated for SI (defined as either the need for hospitalization with antibacterial therapy for a potentially fatal infection or death caused by the infection). Standardized SI rate was calculated per 100 patient years. Patients with and without SI were compared. Bivariate and multivariate logistic and Cox regression models were built to calculate associated factors to SI and relative risks. RESULTS A total of 353 jSLE patients were included: 88.7% female, 14.3 years (± 2.9) of age at diagnosis, 16.0 years (± 9.3) of disease duration and 31.5 years (±10.5) at end of follow-up. A total of 104 (29.5%) patients suffered 205 SI (1, 55.8%; 2-5, 38.4%; and ≥6, 5.8%). Incidence rate was 3.7 (95%CI: 3.2-4.2) SI per 100 patient years. Respiratory location and bacterial infections were the most frequent. Higher number of SLE classification criteria, SLICC/ACR DI score and immunosuppressants use were associated to the presence of SI. Associated factors to shorter time to first infection were higher number of SLE criteria, splenectomy and immunosuppressants use. CONCLUSIONS The risk of SI in jSLE patients is significant and higher than aSLE. It is associated to higher number of SLE criteria, damage accrual, some immunosuppressants and splenectomy.
Collapse
Affiliation(s)
- Vicenç Torrente-Segarra
- Department of Rheumatology. Hospital Comarcal de l'Alt Penedès-Garraf., Vilafranca del Penedès (Spain), C/ de l'Espirall, s/n, 08720, Vilafranca del Penedès, Spain.
| | | | - Íñigo Rúa-Figueroa
- Rheumatology Department, Doctor Negrín University Hospital of Gran Canaria, Spain.
| | | | | | | | | | | | - Coral Mouriño-Rodríguez
- Rheumatology Department, Complexo Hospitalario Universitario de Vigo (Spain), IRIDIS Group, Instituto de Investigación Sanitaria Galicia Sur (IISGS), Vigo, Spain.
| | - Loreto Horcada
- Rheumatology Department, Navarra Hospital, Navarra, Pamplona, Spain
| | - Cristina Bohórquez
- Rheumatology Department, Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain
| | - Carlos Montilla
- Rheumatology Department, Salamanca Clinic University Hospital, Castilla y León, Salamanca, Spain
| | - Eva Salgado
- Rheumatology Department, Hospital Complex of Ourense, Ourense, Spain.
| | | | - Ricardo Blanco
- Rheumatology Department, Marqués de Valdecilla University Hospital, Cantabria, Santander, Spain.
| | - José Luis Andreu
- Rheumatology Department, Puerta de Hierro-Majadahonda Hospital, Madrid, Spain.
| | | | - Lorena Expósito
- Rheumatology Department, Hospital Univ. De Canarias, Tenerife, Tenerife, Spain
| | - Marian Gantes
- Rheumatology Department, Tenerife Clinic Hospital, Islas Canarias, Santa Cruz de Tenerife, Spain
| | | | | | - Nuria Lozano-Rivas
- Rheumatology Department, Virgen de la Arrixaca University Hospital, Murcia, Murcia, Spain
| | - Gema Bonilla
- Rheumatology Department, La Paz University Hospital, Madrid, Madrid, Spain.
| | - Ana Lois Iglesias
- Rheumatology Department, Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain
| | - Paula Rubio-Muñoz
- Rheumatology Department, Germans Trias i Pujol University Hospital, Badalona, Spain
| | - Juan Ovalles
- Rheumatology Department, Hospital Gregorio Marañón, Madrid, Spain
| | - Eva Tomero
- Rheumatology Department, Hospital de la Princesa, Madrid, Spain
| | - Alina Boteanu
- Rheumatology Department, Hospital Ramon y Cajal, Madrid, Spain
| | - Javier Narvaez
- Rheumatology Department, Hospital de Bellvitge, Hospitalet Llobregat, Spain.
| | - Mercedes Freire
- Rheumatology Department, Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain.
| | - Paloma Vela
- Rheumatology Department, Hospital Universitario de Alicante, Alicante, Spain
| | | | - Antonio Juan Mas
- Rheumatology Department, Hospital Son Llatzer de Mallorca, Mallorca, Spain.
| | | | - Enrique Raya
- Rheumatology Department, Hospital Clínico San Cecilio de Granada, Granada, Spain
| | - Mireia Moreno
- Rheumatology Department, Parc Taulí de Sabadell, Sabadell, Spain
| | - M L Velloso-Feijoo
- Rheumatology Department, Hospital Universitario de Valme, Sevilla, Spain
| | - Gregorio Soler
- Rheumatology Department, Hospital de Marinabaixa, Villajoyosa, Spain
| | | | - José M Pego-Reigosa
- Rheumatology Department, University Hospital Complex, IRIDIS Group, Instituto de Investigación Sanitaria Galicia Sur (IISGS), Vigo, Spain.
| | | |
Collapse
|
4
|
Soler G, Viguera J, Villacampa M, Losa F, Frago R, Legido R, Camacho D, Gomez E, Mata F, Cambray M. ROLE OF PRE-OPERATIVE SHORT COURSE RADIATION IN FRAIL PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER (LARC). J Geriatr Oncol 2019. [DOI: 10.1016/s1879-4068(19)31176-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
5
|
Fizazi K, Maillard A, Penel N, Baciarello G, Allouache D, Daugaard G, Van de Wouw A, Soler G, Vauleon E, Chaigneau L, Janssen R, Losa Gaspa F, Morales Barrera R, Balana C, Tosi D, Chauffert B, Schnabel C, Martineau G, Culine S, Borget I. A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394] [Citation(s) in RCA: 109] [Impact Index Per Article: 21.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
|
6
|
Soler G, Ruffinelli Rodriguez J, Legido R, Martinez Villacampa M, Perez F, Pardo-Burdalo B, Marín J, Morilla Ruiz I, Heras Lopez L, Vazquez S, Recalde S, Plana Serrahima M, Santos C, Mulet Margalef N, Teule A, Salazar R, Galan M, Saldaña J. Detection of frailty in elderly colorectal càncer patients: Is G8 a good screening tool? Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.116] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Domenech Viñolas M, Santos C, Pérez J, Varela M, Martinez Villacampa M, Teule A, Ruffinelli Rodriguez J, Mulet Margalef N, Soler G, Ortega A, Bergamino M, SanJuan X, Torras J, Ramos E, Salazar R. KRAS mutations as a prognostic factor after metastasectomy in colorectal cancer patients. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Amoros E, Soler G, Pascal L, Ndiaye A, Gadegbeku B, Martin JL. Estimation of the number of seriously injured road users in France, 2006–2015. Rev Epidemiol Sante Publique 2018. [DOI: 10.1016/j.respe.2018.05.258] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
9
|
Marín J, Soler G, Martínez-Villacampa M, Vázquez S, Vivas CS, Margalef NM, Teule A, Salazar R. G8 screening tool for treatment decision-making in elderly colorectal cancer patients. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
Hummel T, Whitcroft KL, Andrews P, Altundag A, Cinghi C, Costanzo RM, Damm M, Frasnelli J, Gudziol H, Gupta N, Haehne A, Holbrook E, Hong SC, Hornung D, Hüttenbrink KB, Kamel R, Kobayashi M, Konstantinidis I, Landis BN, Leopold DA, Macchi A, Miwa T, Moesges R, Mullol J, Mueller CA, Ottaviano G, Passali GC, Philpott C, Pinto JM, Ramakrishnan VJ, Rombaux P, Roth Y, Schlosser RA, Shu B, Soler G, Stjärne P, Stuck BA, Vodicka J, Welge-Luessen A. Position paper on olfactory dysfunction. Rhinology 2018. [PMID: 29528615 DOI: 10.4193/rhino16.248] [Citation(s) in RCA: 373] [Impact Index Per Article: 62.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Background Olfactory dysfunction is an increasingly recognised condition, associated with reduced quality of life and major
health outcomes such as neurodegeneration and death. However, translational research in this field is limited by heterogeneity in methodological approach, including definitions of impairment, improvement and appropriate assessment techniques. Accordingly, effective treatments for smell loss are limited. In an effort to encourage high quality and comparable work in this field, among others, we propose the following ideas and recommendations. Whilst the full set of recommendations are outlined in the main document, points include the following:
• Patients with suspected olfactory loss should undergo a full examination of the head and neck, including rigid nasal endoscopy
with small diameter endoscopes.
• Subjective olfactory assessment should not be undertaken in isolation, given its poor reliability.
• Psychophysical assessment tools used in clinical and research settings should include reliable and validated tests of odour
threshold, and/or one of odour identification or discrimination.
• Comprehensive chemosensory assessment should include gustatory screening.
• Smell training can be helpful in patients with olfactory loss of several aetiologies. Conclusions We hope the current manuscript will encourage clinicians and researchers to adopt a common language, and in so doing, increase the methodological quality, consistency and generalisability of work in this field.
Collapse
|
11
|
Gironés R, Morilla I, Guillen-Ponce C, Torregrosa MD, Paredero I, Bustamante E, Del Barco S, Soler G, Losada B, Visa L, Llabrés E, Fox B, Firvida JL, Blanco R, Antonio M, Aparisi F, Pi-Figueras M, Gonzalez-Flores E, Molina-Garrido MJ, Saldaña J. Geriatric oncology in Spain: survey results and analysis of the current situation. Clin Transl Oncol 2017; 20:1087-1092. [PMID: 29327240 PMCID: PMC6061214 DOI: 10.1007/s12094-017-1813-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2017] [Accepted: 11/16/2017] [Indexed: 11/30/2022]
Abstract
Introduction Geriatric oncology (GO) is a discipline that focuses on the management of elderly patients with cancer. The Spanish Society of Medical Oncology (SEOM) created a Working group dedicated to geriatric oncology in February 2016. Objectives The main goal of this study was to describe the current situation in Spain regarding the management of elderly cancer patients through an online survey of medical oncologists. Methods A descriptive survey was sent to several hospitals by means of the SEOM website. A personal e-mail was also sent to SEOM members. Results Between March 2016 and April 2017, 154 answers were collected. Only 74 centers (48%) had a geriatrics department and a mere 21 (14%) medical oncology departments had a person dedicated to GO. The vast majority (n = 135; 88%) had the perception that the number of elderly patients with cancer seen in clinical practice had increased. Eighteen (12%) oncologists had specific protocols and geriatric scales were used at 55 (31%) centers. Almost all (92%) claimed to apply special management practices using specific tools. There was agreement that GO afforded certain potential advantages. Finally, 99% of the oncologists surveyed believed it and that training in GO had to be improved. Conclusions From the nationwide survey promoted by the Spanish Geriatric Oncology Working Group on behalf of SEOM, we conclude that there is currently no defined care structure for elderly cancer patients. There is an increasing perception of the need for training in GO. This survey reflects a reality in which specific needs are perceived.
Collapse
Affiliation(s)
- R Gironés
- Medical Oncology Unit. Hospital Lluís Alcanyís, Crta Xàtiva A Silla Km 2, Xàtiva, 46800, Valencia, Spain.
| | - I Morilla
- Institut Català D'Oncologia-L'Hospitalet, Barcelona, Spain
| | | | | | - I Paredero
- Hospital Universitario Dr Peset, Valencia, Spain
| | - E Bustamante
- Althaia, Xarxa Assistencial I Universitaria Manresa, Barcelona, Spain
| | - S Del Barco
- Hospital Universitari Dr. Josep Trueta. ICO Girona, Girona, Spain
| | - G Soler
- Institut Català D'Oncologia-L'Hospitalet, Barcelona, Spain
| | - B Losada
- Hospital Universitario de Fuenlabrada, Madrid, Spain
| | - L Visa
- Hospital Del Mar, Barcelona, Spain
| | - E Llabrés
- Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain
| | - B Fox
- Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - J L Firvida
- Complejo Hospitalario Universitario de Ourense (CHUO), Ourense, Spain
| | - R Blanco
- Consorci Sanitari de Terrassa, Barcelona, Spain
| | - M Antonio
- Institut Català D'Oncologia-L'Hospitalet, Barcelona, Spain
| | - F Aparisi
- Hospital General de Valencia, Valencia, Spain
| | | | | | | | - J Saldaña
- Institut Català D'Oncologia-L'Hospitalet, Barcelona, Spain
| | | |
Collapse
|
12
|
Losa F, Soler G, Casado A, Estival A, Fernández I, Giménez S, Longo F, Pazo-Cid R, Salgado J, Seguí MÁ. SEOM clinical guideline on unknown primary cancer (2017). Clin Transl Oncol 2017; 20:89-96. [PMID: 29230692 PMCID: PMC5785607 DOI: 10.1007/s12094-017-1807-y] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2017] [Accepted: 11/13/2017] [Indexed: 12/16/2022]
Abstract
Cancer of unknown primary site is a histologically confirmed cancer that manifests in advanced stage, with no identifiable primary site following standard diagnostic procedures. Patients are initially categorized based on the findings of the initial biopsy: adenocarcinoma, squamous-cell carcinoma, neuroendocrine carcinoma, and poorly differentiated carcinoma. Appropriate patient management requires understanding several clinical and pathological features that aid in identifying several subsets of patients with more responsive tumors.
Collapse
Affiliation(s)
- F Losa
- Hospital de Sant Joan Despí Moisés Broggi, Sant Joan Despí, Barcelona, Spain.
| | - G Soler
- Hospital Durán i Reynals (ICO-L'Hospitalet), Barcelona, Spain
| | - A Casado
- Hospital Universitario Clínico San Carlos, Madrid, Spain
| | - A Estival
- Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
| | - I Fernández
- Hospital Alvaro Cunqueiro-Complejo Hospitalario Universitario, Vigo, Spain
| | - S Giménez
- Hospital Universitari I Politècnic la Fe, Valencia, Spain
| | - F Longo
- Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - R Pazo-Cid
- Hospital Universitario Miguel Servet, Zaragoza, Spain
| | - J Salgado
- Complejo Hospitalario de Navarra, Pamplona, Spain
| | - M Á Seguí
- Parc Taulí Sabadell, Hospital Universitari, Sabadell, Barcelona, Spain
| |
Collapse
|
13
|
Hummel T, Whitcroft KL, Andrews P, Altundag A, Cinghi C, Costanzo RM, Damm M, Frasnelli J, Gudziol H, Gupta N, Haehner A, Holbrook E, Hong SC, Hornung D, Hüttenbrink KB, Kamel R, Kobayashi M, Konstantinidis I, Landis BN, Leopold DA, Macchi A, Miwa T, Moesges R, Mullol J, Mueller CA, Ottaviano G, Passali GC, Philpott C, Pinto JM, Ramakrishnan VJ, Rombaux P, Roth Y, Schlosser RA, Shu B, Soler G, Stjärne P, Stuck BA, Vodicka J, Welge-Luessen A. Position paper on olfactory dysfunction. Rhinology 2017. [PMID: 28623665 DOI: 10.4193/rhin16.248] [Citation(s) in RCA: 95] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Olfactory dysfunction is an increasingly recognised condition, associated with reduced quality of life and major health outcomes such as neurodegeneration and death. However, translational research in this field is limited by heterogeneity in methodological approach, including definitions of impairment, improvement and appropriate assessment techniques. Accordingly, effective treatments for smell loss are limited. In an effort to encourage high quality and comparable work in this field, among others, we propose the following ideas and recommendations. Whilst the full set of recommendations are outlined in the main document, points include the following: - Patients with suspected olfactory loss should undergo a full examination of the head and neck, including rigid nasal endoscopy with small diameter endoscopes. - Subjective olfactory assessment should not be undertaken in isolation, given its poor reliability. - Psychophysical assessment tools used in clinical and research settings should include reliable and validated tests of odour threshold, and/or one of odour identification or discrimination. - Comprehensive chemosensory assessment should include gustatory screening. - Smell training can be helpful in patients with olfactory loss of several aetiologies. CONCLUSIONS We hope the current manuscript will encourage clinicians and researchers to adopt a common language, and in so doing, increase the methodological quality, consistency and generalisability of work in this field.
Collapse
Affiliation(s)
- T Hummel
- Smell and Taste Clinic, Department of Otorhinolaryngology, TU Dresden, Dresden, Germany
| | - K L Whitcroft
- Smell and Taste Clinic, Department of Otorhinolaryngology, TU Dresden, Dresden, Germany
| | - P Andrews
- UCL Ear Institute, Faculty of Brain Sciences, University College London, London, UK
| | - A Altundag
- Department of Otorhinolaryngoglogy, Istanbul Surgery Hospital, Istanbul, Turkey
| | - C Cinghi
- Department of Otolaryngology; Eskisehir Osmangazi University, Istanbul, Turkey
| | - R M Costanzo
- Smell and Taste Disorders Center, Department of Otolaryngology Head and Neck Surgery, VCU School of Medicine, Richmond, VA, USA
| | - M Damm
- Department of Otorhinolaryngology, Head and Neck Surgery, University of Cologne Medical Center, Cologne, Germany
| | - J Frasnelli
- Research Chair in Chemosensory Neuroanatomy, Department of Anatomy, Universite du Quebec a Trois-Rivieres, Trois-Rivieres, QC, Canada
| | - H Gudziol
- Department of Otorhinolaryngology, University of Jena, Jena, Germany
| | - N Gupta
- Department of Otorhinolaryngology, University College of Medical Sciences and GTB Hospital, Delhi, India
| | - A Haehner
- Smell and Taste Clinic, Department of Otorhinolaryngology, TU Dresden, Dresden, Germany
| | - E Holbrook
- Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA
| | - S C Hong
- Department of Otorhinolaryngology, Konkuk University Medical Center, Hwayang-dong, Gwangjin-gu, Seoul, South Korea
| | - D Hornung
- Dept. of Biology, St. Lawrence University, Canton, NY, USA
| | | | - R Kamel
- Department of Otorhinolaryngology, Cairo University, Cairo, Egypt
| | - M Kobayashi
- Department of Otorhinolaryngology-Head and Neck Surgery, Mie University Graduate School of Medicine, Mie, Japan
| | - I Konstantinidis
- Smell and Taste Clinic, Second Academic Otorhinolaryngology Department, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - B N Landis
- Department for ENT, Head and Neck Surgery, Bern University Hospital, Bern, Switzerland
| | - D A Leopold
- Division of Otorhinolaryngology-Head and Neck Surgery, Department of Surgery, University of Vermont Medical Center, Burlington, Vermont, USA
| | - A Macchi
- ENT Clinic, University of Insubria, ASST, sette laghi, Varese, Italy
| | - T Miwa
- Department of Otorhinolaryngology, Kanazawa Medical University, Uchinada, Kahoku, Ishikawa, Japan
| | - R Moesges
- Institute of Medical Statistics, Informatics and Epidemiology, University Hospital of Cologne, Cologne, Germany
| | - J Mullol
- Rhinology Unit and Smell Clinic, IDIBAPS, University of Barcelona, Barcelona, Catalonia, Spain
| | - C A Mueller
- Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria
| | - G Ottaviano
- Department of Neurosciences DNS, Otolaryngology Section, University, Padua, Italy
| | - G C Passali
- Head and Neck section, Department of Aging, Neurosciences, Head and Neck and Orthopedic; Catholic University of Sacred heart, A. Gemelli Hospital Foundation, Rome, Italy
| | - C Philpott
- Norwich Medical School, University of East Anglia, Norwich, UK
| | - J M Pinto
- Section of Otolaryngology-Head and Neck Surgery, The University of Chicago Medicine and Biological Sciences, Chicago, IL, USA
| | - V J Ramakrishnan
- Departments of Otolaryngology and Neurosurgery, University of Colorado, Aurora, CO, USA
| | - P Rombaux
- Universite Catholique de Louvain, Institute of Neurosciences, Unit of Otorhinolaryngology, Brussels, Belgium
| | - Y Roth
- The Institute for Nose and Sinus Therapy and Clinical Investigations, Department of Otolaryngology - Head and Neck Surgery, Edith Wolfson Medical Center, Tel Aviv University Sackler Faculty of Medicine, Holon, Israel
| | - R A Schlosser
- Department of Otolaryngology, Head and Neck Surgery, Medical Univeristy of South Carolina, Charleston, SC, USA
| | - B Shu
- Department of Otolaryngology, Taipei Veterans General Hospital, National Yang Ming University School of Medicine Faculty of Medicine, Taipei, Taiwan
| | - G Soler
- Division of Otorhinolaryngology, Area of Smell and Taste, Hospital de Clinicas, University of Buenos Aires, Buenos Aires City, Argentina
| | - P Stjärne
- Section of Rhinology, Department of Otorhinolaryngology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden
| | - B A Stuck
- Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Essen, University Duisburg-Essen, Germany
| | - J Vodicka
- Department of Otorhinolaryngology and Head and Neck Surgery, Hospital Pardubice, Faculty of Health Studies, University of Pardubice, Pardubice, Czech Republic
| | - A Welge-Luessen
- University Hospital Basel - Otorhinolaryngology, Basel, Switzerland
| |
Collapse
|
14
|
Gravalos C, Carrato A, Tobeña M, Pulido EG, Soler G, Vieitez J, Robles L, Valladares-Ayerbes M, Polo E, Limon M, Safont M, Lopez C, Alfonso PG, Aranda E. Phase II clinical trial with axitinib as maintenance therapy in patients (p) with metastatic colorectal carcinoma (CRC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Domenech Viñolas M, Santos C, Pérez Martín Francisco J, Varela M, Merche M, Grasselli J, Teule A, Soler G, Mulet Margalef N, Bergamino Sirven M, Ortega Franco A, Sanjuan X, Salazar R. P-160 Impact of KRAS mutation on patterns of metastasis in a series of colorectal cancer patients. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw199.154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Soler G, Bernal-Vicente A, Antón AI, Torregrosa JM, Caparrós-Pérez E, Sánchez-Serrano I, Martínez-Pérez A, Sánchez-Vega B, Vicente V, Ferrer-Marin F. The JAK2 46/1 haplotype does not predispose to CALR-mutated myeloproliferative neoplasms. Ann Hematol 2014; 94:789-94. [DOI: 10.1007/s00277-014-2266-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2014] [Accepted: 11/23/2014] [Indexed: 10/24/2022]
|
17
|
Alonso-Colmenar L, Zapata A, Fortea P, Flores M, Ortuño F, Soler G, García M, García-Cantalejo J. 579 Eph/ephrin-B interactions modulate a BAFF-R/TACI dependent survival of chronic lymphocytic leukemia (CLL) cells mediated in vitro by bone marrow stromal cells. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70705-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
18
|
Barrios P, Crusellas O, Castellvi J, Losa F, Soler G, Fuste V, Martin M, Galofre G, Ramos I. Peritoneal Carcinomatosis (Pc) from Colo-Rectal Origin. Results of 200 Patients Treated By Radical Surgery (Crs) Plus Hyperthermic Intraperitoneal Chemotherapy (Hipec) at the Catalonian Peritoneal Carcinomatosis Program (Spain). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu333.96] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
19
|
Ramos I, Crusellas Maña O, Castellvi J, Galofre G, Soler G, Losa F, Martin M, Barrios P. Consecutive Complete Radical Surgery (Crs) Plus Hyperthermic Intraperitoneal Chemotherapy (Hipec) Procedures in Patients with Peritoneal Carcinomatosis (Pc). Clinical Results and Survival According to Malignancy Type (Spain). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu334.62] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
20
|
Galofre G, Ramos I, Crusellas O, Castellvi J, Losa F, Soler G, Fuster V, Martin M, Barrios Sanchez P. Peritoneal Carcinomatosis (Pc) from Gastric Origin. 26 Consecutive Patients Treated By Radical Surgery (Crs) Plus Hyperthermic Intraperitoneal Chemotherapy (Hipec). Results from the Catalonian Peritoneal Carcinomatosis Programme (Spain). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu334.60] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
21
|
Soler G, Kaltenbach S, Dobbelstein S, Broccardo C, Radford I, Mozziconacci MJ, Bernard OA, Penard-Lacronique V, Delabesse E, Romana SP. Identification of GSX2 and AF10 as NUP98 partner genes in myeloid malignancies. Blood Cancer J 2013; 3:e124. [PMID: 23852159 PMCID: PMC3730198 DOI: 10.1038/bcj.2013.20] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Affiliation(s)
- G Soler
- 1] Service de Cytogénétique, Hôpital Necker, AP-HP, Paris, France [2] Université Paris Descartes, Paris, France [3] INSERM U985, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Santos C, López-Doriga A, Navarro M, Mateo J, Biondo S, Martínez Villacampa M, Soler G, Sanjuan X, Paules MJ, Laquente B, Guinó E, Kreisler E, Frago R, Germà JR, Moreno V, Salazar R. Clinicopathological risk factors of Stage II colon cancer: results of a prospective study. Colorectal Dis 2013; 15:414-22. [PMID: 22974322 DOI: 10.1111/codi.12028] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
AIM Adjuvant 5-fluorouracil based chemotherapy has demonstrated benefit in Stage III colon cancer but still remains controversial in Stage II. The aim of this study was to analyse the prognostic impact of clinicopathological factors that may help guide treatment decisions in Stage II colon cancer. METHOD Between 1996 and 2006 data from patients diagnosed with colorectal cancer at Hospital Universitari Bellvitge and its referral comprehensive cancer centre Institut Català d'Oncologia/L'Hospitalet were prospectively included in a database. We identified 432 patients with Stage II colon cancer operated on at Hospital Universitari Bellvitge. The 5-year relapse-free survival (RFS) and colon-cancer-specific survival (CCSS) were determined. RESULTS The 5-year RFS and CCSS were 83% and 88%, respectively. Lymphovascular or perineural invasion was associated with RFS [hazard ratio (HR) 1.84; 95% CI 1.01-3.35]. Gender (women, HR 0.48; 95% CI 0.23-1) and lymphovascular or perineural invasion (HR 3.51; 95% CI 1.86-6.64) together with pT4 (HR 2.79; 95% CI 1.44-5.41) influenced CCSS. In multivariate analysis pT4 and lymphovascular or perineural invasion remained significantly associated with CCSS. We performed a risk index with these factors with prognostic impact. Patients with pT4 tumours and lymphovascular or perineural invasion had a 5-year CCSS of 61%vs the 93% (HR 5.87; 95 CI 2.46-13.97) of those without any of these factors. CONCLUSION pT4 and lymphatic, venous or perineural invasion are confirmed as significant prognostic factors in Stage II colon cancer and should be taken into account in the clinical validation process of new molecular prognostic factors.
Collapse
Affiliation(s)
- C Santos
- Department of Medical Oncology, Institut Català d'Oncologia - Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Redondo JI, Suesta P, Serra I, Soler C, Soler G, Gil L, Gómez-Villamandos RJ. Retrospective study of the prevalence of postanaesthetic hypothermia in dogs. Vet Rec 2012; 171:374. [PMID: 22922707 DOI: 10.1136/vr.100476] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The anaesthetic records of 1525 dogs were examined to determine the prevalence of postanaesthetic hypothermia, its clinical predictors and consequences. Temperature was recorded throughout the anaesthesia. At the end of the procedure, details coded in were: hyperthermia (>39.50°C), normothermia (38.50°C-39.50°C), slight (38.49°C-36.50°C), moderate (36.49°C-34.00°C) and severe hypothermia (<34.00°C). Statistical analysis consisted of multiple regression to identify the factors that are associated with the temperature at the end of the procedure. Before premedication, the temperature was 38.7 ± 0.6°C (mean ± sd). At 60, 120 and 180 minutes from induction, the temperature was 36.7 ± 1.3°C, 36.1 ± 1.4°C and 35.8 ± 1.5°C, respectively. The prevalence of hypothermia was: slight, 51.5 per cent (95 per cent CI 49.0 to 54.0 per cent); moderate, 29.3 per cent (27.1-31.7 per cent) and severe: 2.8% (2.0-3.7%). The variables that associated with a decrease in the temperature recorded at the end of the anaesthesia were: duration of the preanesthetic time, duration of the anaesthesia, physical condition (ASA III and ASA IV dogs showed lower temperatures than ASA I dogs), the reason for anaesthesia (anaesthesia for diagnostic procedures or thoracic surgery reduce the temperature when compared with minor procedures), and the recumbency during the procedure (sternal and dorsal recumbencies showed lower temperatures than lateral recumbency). The temperature before premedication and the body surface (BS) were associated with a higher temperature at the end of the anaesthesia, and would be considered as protective factors.
Collapse
Affiliation(s)
- J I Redondo
- Departamento de Medicina y Cirugía Animal, Facultad de Veterinaria, Instituto de Ciencias Biomédicas, Universidad CEU Cardenal Herrera, Valencia, Spain
| | | | | | | | | | | | | |
Collapse
|
24
|
Redondo JI, Suesta P, Gil L, Soler G, Serra I, Soler C. Retrospective study of the prevalence of postanaesthetic hypothermia in cats. Vet Rec 2012; 170:206. [DOI: 10.1136/vr.100184] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- J. I. Redondo
- Department of Animal Medicine and Surgery; Cardenal Herrera CEU University; Avenida Seminario s/n 46113 Moncada Valencia Spain
| | - P. Suesta
- Department of Animal Medicine and Surgery; Cardenal Herrera CEU University; Avenida Seminario s/n 46113 Moncada Valencia Spain
| | - L. Gil
- Department of Animal Medicine and Surgery; Cardenal Herrera CEU University; Avenida Seminario s/n 46113 Moncada Valencia Spain
| | - G. Soler
- Department of Animal Medicine and Surgery; Cardenal Herrera CEU University; Avenida Seminario s/n 46113 Moncada Valencia Spain
| | - I. Serra
- Department of Animal Medicine and Surgery; Cardenal Herrera CEU University; Avenida Seminario s/n 46113 Moncada Valencia Spain
| | - C. Soler
- Department of Animal Medicine and Surgery; Cardenal Herrera CEU University; Avenida Seminario s/n 46113 Moncada Valencia Spain
| |
Collapse
|
25
|
Caballero S, Cardeñosa D, Soler G, Hyde J. Application of multiplex PCR approaches for shark molecular identification: feasibility and applications for fisheries management and conservation in the Eastern Tropical Pacific. Mol Ecol Resour 2011; 12:233-7. [PMID: 22067369 DOI: 10.1111/j.1755-0998.2011.03089.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Here we describe the application of new and existing multiplex PCR methodologies for shark species molecular identification. Four multiplex systems (group ID, thresher sharks, hammerhead sharks and miscellaneous shark) were employed with primers previously described and some designed in this study, which allow for species identification after running PCR products through an agarose gel. This system was implemented for samples (bodies and fins) collected from unidentified sharks landed in the port of Buenaventura and from confiscated tissues obtained from illegal fishing around the Malpelo Island Marine Protected Area, Pacific Coast of Colombia. This method has allowed reliable identification, to date, of 407 samples to the genus and/or species levels, most of them (380) identified as the pelagic thresher shark (Alopias pelagicus). Another seven samples were identified as scalloped hammerhead sharks (Sphyrna lewini). This is an easy-to-implement and reliable identification method that could even be used locally to monitor shark captures in the main fishing ports of developed and developing countries.
Collapse
Affiliation(s)
- S Caballero
- Laboratorio de Ecología Molecular de Vertebrados Acuáticos-LEMVA, Departamento de Ciencias Biológicas, Universidad de los Andes, Carrera 1 No. 18A-10, Bogotá, Colombia.
| | | | | | | |
Collapse
|
26
|
Sastre J, Aranda E, Grávalos C, Massutí B, Varella-Garcia M, Rivera F, Soler G, Carrato A, Manzano JL, Díaz-Rubio E, Hidalgo M. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Crit Rev Oncol Hematol 2009; 77:78-84. [PMID: 20042346 DOI: 10.1016/j.critrevonc.2009.11.005] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2009] [Revised: 11/10/2009] [Accepted: 11/26/2009] [Indexed: 12/11/2022] Open
Abstract
PURPOSE to evaluate the efficacy and safety of first-line single-agent cetuximab in fit elderly patients with metastatic colorectal cancer, as well as potential molecular predictive factors for efficacy. PATIENTS AND METHODS patients aged 70 or older with metastatic CRC without criteria for frailty and no prior treatment for advanced disease were treated with single-agent cetuximab 400mg/m(2) followed by weekly 250mg/m(2) until disease progression or unacceptable toxicity. RESULTS forty-one patients were included. Two patients achieved a complete response and 4 patients had a partial response for an overall response rate of 14.6%. Fifteen patients (36.6%) remained stable. Median time to progression was 2.9 months and median overall survival 11.1 months despite two-third of patients received chemotherapy at progression. Forty-five percent of EGFR gene copy number positive patients by FISH were progression-free at 12 weeks, in contrast with 12% of FISH negative patients (p=0.04). Grade 3 skin toxicity was reported in 5 patients (12.2%). Hypersensitivity infusion reactions were not reported and there were no toxic deaths. CONCLUSION cetuximab is a safe monoclonal antibody with moderate activity in first-line metastatic colorectal cancer, but the present study does not support the use of cetuximab as single-agent in first-line fit elderly patients with metastatic CRC.
Collapse
Affiliation(s)
- J Sastre
- HC San Carlos, Madrid, Center affíliated to the Red Temática de Investigación Cooperativa (RD06/0020/0021), Instituto Carlos III, Spanish Ministry of Science and Innovation, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Petit A, Ragu C, Della-Valle V, Mozziconacci MJ, Lafage-Pochitaloff M, Soler G, Schluth C, Radford I, Ottolenghi C, Bernard OA, Penard-Lacronique V, Romana SP. NUP98-HMGB3: a novel oncogenic fusion. Leukemia 2009; 24:654-8. [PMID: 19956199 DOI: 10.1038/leu.2009.241] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
28
|
Soler G, Nusbaum S, Varet B, Macintyre EA, Vekemans M, Romana SP, Radford-Weiss I. LRRFIP1, a new FGFR1 partner gene associated with 8p11 myeloproliferative syndrome. Leukemia 2009; 23:1359-61. [PMID: 19369959 DOI: 10.1038/leu.2009.79] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
29
|
Romeo M, Soler G, Villacampa MM, Laquente B, Doriga AL, Pisa A, Rey M, Santos C, Salazar R, Lluch JRG. Cost-effectiveness analysis of cetuximab as third-line treatment in metastatic colorectal cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
30
|
Pisa A, Calvo M, Pérez X, Villacampa MM, Soler G, Laquente B, Santos C, Kreissler E, Salazar R, Lluch JRG. Descriptive study of patients with peritoneal carcinomatosis and colorectal cancer: An overall survival clinical prognostic score. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
31
|
Sahli R, Canioni D, Couturier J, Soler G, Mathiot C, Galatoire O, Rouic LLL, Puttermann M, Hermine O, Validire P, Morax S, Brousse N, Decaudin D. Bilateral MALT-type ocular adnexal lymphoma with marginal zone lymphoma leukaemic cells and ophthalmological diffuse large B cell lymphoma. Br J Ophthalmol 2008; 92:579-80. [DOI: 10.1136/bjo.2007.123356] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
32
|
Angulo B, Suarez-Gauthier A, Lopez-Rios F, Medina PP, Conde E, Tang M, Soler G, Lopez-Encuentra A, Cigudosa JC, Sanchez-Cespedes M. Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification. J Pathol 2008; 214:347-56. [PMID: 17992665 DOI: 10.1002/path.2267] [Citation(s) in RCA: 76] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The development of targeted therapies creates a need to discriminate tumours accurately by their histological and genetic characteristics. Here, we aim to identify gene expression profiles and single markers that recapitulate the pathological and genetic background of non-small cell lung cancer (NSCLC). We performed cDNA microarray analysis on a series of 69 NSCLCs, with known mutation status for important genes, and six normal lung tissues. Unsupervised cluster analysis segregated normal lungs from lung tumours and lung tumours according to their histopathology and the presence of EGFR mutations. Several transcripts were highly overexpressed (by approximately 20 times) in squamous cell carcinomas (SCCs) relative to adenocarcinomas (ACs) and confirmed by immunohistochemistry in an independent cohort of 75 lung tumours. Expression of 13 genes constituted the most prominent hallmarks of EGFR-mutant tumours, including increased levels of proline dehydrogenase (PRODH) and down-regulation of X-box binding protein 1 (XBP1). No genes were differentially expressed, with a fold change >or= 4 or <or=0.25 and a significance level of 5% false-discovery rate, in tumours carrying mutations of TP53 or KRAS. In addition, we organized gene expression data by the position of each gene in the chromosome and observed a cluster of highly expressed genes in chromosome 3q, including PIK3CA, that was characteristic of SCCs. FISH analysis demonstrated a strong statistically significant association between increased levels of PIK3CA expression in these tumours and gene amplification (p < 0.0001; t-test). In conclusion, histopathological phenotypes and, likely, the presence of EGFR mutations confer lung tumours with a marked pattern of gene expression. Moreover, our cDNA microarray analysis identified increased PIK3CA expression due to gene amplification in lung squamous cell carcinomas: this may represent a marker of sensitivity to therapy with PI3K inhibitors.
Collapse
Affiliation(s)
- B Angulo
- Lung Cancer Group, Spanish National Cancer Centre (CNIO), 28029 Madrid, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Majem M, Galán M, Pérez FJ, Muñoz M, Chicote S, Soler G, Navarro M, Martínez-Villacampa M, García del Muro X, Dotor E, Laquente B, Germà JR. The oncology acute toxicity unit (OATU): an outpatient facility for improving the management of chemotherapy toxicity. Clin Transl Oncol 2008; 9:784-8. [PMID: 18158982 DOI: 10.1007/s12094-007-0140-2] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
OBJECTIVE To provide an outpatient facility to improve the management of chemotherapy toxicity in cancer patients. PATIENTS AND METHODS We set up an oncology acute toxicity unit (OATU) to improve toxicity management. A telephone helpline was the initial contact which filters out inappropriate non-toxicity-related events. Patients were provided an information booklet describing the possible side effects of the chemotherapy and the helpline telephone number. A specialist nurse received the calls and consulted the doctor if necessary. Depending on requirements, the patient's problem was resolved by telephone, or a consultation visit at the OATU was arranged. RESULTS Between February 1999 and August 2001, 1126 patients made 2007 contacts with the OATU. The most common tumours were breast (26%), colorectal (20%) and lung (20%). The telephone helpline was used in 87% of contacts and 37% were considered inappropriate. Of the 1263 appropriate contacts, the most frequent chemotherapy schedules that had been administered were 5FU-leucovorin (11.2%) and CMF (10.4%). The most frequent side effects were fever (35.5%), diarrhoea (18.5%), mucositis (16.2%) and emesis (13%). The problem was resolved by telephone in 48% of cases and 52% required attendance in the OATU, of which 40% required hospital admission, i.e., 21.1% of the initial appropriate helpline contacts. The most frequent reason was Grade 3-4 neutropenic fever (56.5%). CONCLUSIONS The OATU enables prompt and efficient access of patients to medical oncology facilities in the event of toxicity due to chemotherapy. Unnecessary emergency room use is avoided while oncology outpatient and hospitalisation facilities are optimised.
Collapse
Affiliation(s)
- M Majem
- Department of Medical Oncology, Institut Català d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Soler G, Radford-Weiss I, Ben-Abdelali R, Mahlaoui N, Ponceau JF, Macintyre EA, Vekemans M, Bernard OA, Romana SP. Fusion of ZMIZ1 to ABL1 in a B-cell acute lymphoblastic leukaemia with a t(9;10)(q34;q22.3) translocation. Leukemia 2007; 22:1278-80. [PMID: 18007576 DOI: 10.1038/sj.leu.2405033] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
35
|
Redondo JI, Rubio M, Soler G, Serra I, Soler C, Gómez-Villamandos RJ. Normal Values and Incidence of Cardiorespiratory Complications in Dogs During General Anaesthesia. A Review of 1281 Cases. ACTA ACUST UNITED AC 2007; 54:470-7. [DOI: 10.1111/j.1439-0442.2007.00987.x] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
36
|
Arrazubi V, Majem M, Navarro M, Pareja L, Biondo S, Ribes J, Cambray M, Martínez-Villacampa M, Soler G, Germà J. Mortality trends in colorectal cancer (CRC) and influencing factors. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.13527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
13527 Background: A decline in overall cancer death rate was observed in the early 1990s after more than six decades of increase in cancer mortality. Effective prevention, screening and early detection as well as improved treatment strategies may be influencing factors. The aim of this study is to compare the overall survival of patients (pts) with CRC in two different years using our prospective regularly updated register database. Methods: Patients diagnosed of CRC during 1996 and 2000 were included in the study. To analyse the relation between variables the exact Fisher test was used. Survival curves were constructed according to the Kaplan-Meier method and compared by log rank analysis. Analyses were performed using the SPSS package. Results: 289 pts in 1996 and 380 in 2000 were included. Demographic data and tumour characteristics were similar in both groups. 42% of pts in 1996 and 56% in 2000 had received chemotherapy (ChT) (p<0.05). In adjuvant setting, 41.8% of patients with stage II-III colon cancer received ChT in 1996 and 57.5% in 2000 (p=0.019). ChT schedules for advanced CRC included Oxaliplatin and Irinotecan in 23% of ChT in 1996 and in 68% in 2000 (p<0.005). The number of palliative ChT lines was significantly higher in 2000 (p<0.05). Radiotherapy was administered as part of rectal cancer therapy to 48% of pts 1996 and to 60% in 2000 (p=0.05). From those, preoperative radiotherapy was administered to 21% of pts in 1996 and to 66% in 2000 (p<0.05). 4.1% of all pts were lost of follow up. With a median follow up of 104.5 months (m) for 1996 and 56.3 m for 2000, the 5-year overall survival (OS) was 45% and 61.6% respectively (p<0.001). The 5-year disease free survival (DFS) of pts with radical surgery was 73% and 81% respectively (p=0.09). The median survival of pts with radical surgery that relapse during follow up was 13.4 m in 1996 and 17.6 m in 2000 (p<0.04). There were statistical significant differences in OS between 1996 and 2000 in tumour site, stage II-III cancer and males, not in females. DFS for stages II-III was better in 2000, but no significant differences were observed. Conclusions: A positive CRC mortality trend was observed. The influencing factors were related with the use of ChT as an adjuvant treatment and the addition of new drugs in colon cancer therapies as well as preoperative radiotherapy for rectal cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- V. Arrazubi
- Institut Català d′Oncologia, L′Hospitatet de Llobregat, Barcelona, Spain; Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
| | - M. Majem
- Institut Català d′Oncologia, L′Hospitatet de Llobregat, Barcelona, Spain; Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
| | - M. Navarro
- Institut Català d′Oncologia, L′Hospitatet de Llobregat, Barcelona, Spain; Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
| | - L. Pareja
- Institut Català d′Oncologia, L′Hospitatet de Llobregat, Barcelona, Spain; Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
| | - S. Biondo
- Institut Català d′Oncologia, L′Hospitatet de Llobregat, Barcelona, Spain; Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
| | - J. Ribes
- Institut Català d′Oncologia, L′Hospitatet de Llobregat, Barcelona, Spain; Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
| | - M. Cambray
- Institut Català d′Oncologia, L′Hospitatet de Llobregat, Barcelona, Spain; Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
| | - M. Martínez-Villacampa
- Institut Català d′Oncologia, L′Hospitatet de Llobregat, Barcelona, Spain; Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
| | - G. Soler
- Institut Català d′Oncologia, L′Hospitatet de Llobregat, Barcelona, Spain; Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
| | - J. Germà
- Institut Català d′Oncologia, L′Hospitatet de Llobregat, Barcelona, Spain; Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
| |
Collapse
|
37
|
Nadal E, Majem M, Navarro M, Pareja L, Pisa A, Arrazubi V, Pares D, Martinez Villacampa M, Soler G, Germa JR. Intermittent chemotherapy in advanced unresectable colorectal cancer. An option for our patients? J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- E. Nadal
- Inst Catala d’Oncologia, L’Hospitalet de Llobregat, Spain; Bellvitge Hosp, L’Hospitalet De Llobregat, Spain
| | - M. Majem
- Inst Catala d’Oncologia, L’Hospitalet de Llobregat, Spain; Bellvitge Hosp, L’Hospitalet De Llobregat, Spain
| | - M. Navarro
- Inst Catala d’Oncologia, L’Hospitalet de Llobregat, Spain; Bellvitge Hosp, L’Hospitalet De Llobregat, Spain
| | - L. Pareja
- Inst Catala d’Oncologia, L’Hospitalet de Llobregat, Spain; Bellvitge Hosp, L’Hospitalet De Llobregat, Spain
| | - A. Pisa
- Inst Catala d’Oncologia, L’Hospitalet de Llobregat, Spain; Bellvitge Hosp, L’Hospitalet De Llobregat, Spain
| | - V. Arrazubi
- Inst Catala d’Oncologia, L’Hospitalet de Llobregat, Spain; Bellvitge Hosp, L’Hospitalet De Llobregat, Spain
| | - D. Pares
- Inst Catala d’Oncologia, L’Hospitalet de Llobregat, Spain; Bellvitge Hosp, L’Hospitalet De Llobregat, Spain
| | - M. Martinez Villacampa
- Inst Catala d’Oncologia, L’Hospitalet de Llobregat, Spain; Bellvitge Hosp, L’Hospitalet De Llobregat, Spain
| | - G. Soler
- Inst Catala d’Oncologia, L’Hospitalet de Llobregat, Spain; Bellvitge Hosp, L’Hospitalet De Llobregat, Spain
| | - J. R. Germa
- Inst Catala d’Oncologia, L’Hospitalet de Llobregat, Spain; Bellvitge Hosp, L’Hospitalet De Llobregat, Spain
| |
Collapse
|
38
|
Forment J, Gadea J, Huerta L, Abizanda L, Agusti J, Alamar S, Alos E, Andres F, Arribas R, Beltran JP, Berbel A, Blazquez MA, Brumos J, Canas LA, Cercos M, Colmenero-Flores JM, Conesa A, Estables B, Gandia M, Garcia-Martinez JL, Gimeno J, Gisbert A, Gomez G, Gonzalez-Candelas L, Granell A, Guerri J, Lafuente MT, Madueno F, Marcos JF, Marques MC, Martinez F, Martinez-Godoy MA, Miralles S, Moreno P, Navarro L, Pallas V, Perez-Amador MA, Perez-Valle J, Pons C, Rodrigo I, Rodriguez PL, Royo C, Serrano R, Soler G, Tadeo F, Talon M, Terol J, Trenor M, Vaello L, Vicente O, Vidal C, Zacarias L, Conejero V. Development of a citrus genome-wide EST collection and cDNA microarray as resources for genomic studies. Plant Mol Biol 2005; 57:375-91. [PMID: 15830128 DOI: 10.1007/s11103-004-7926-1] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/06/2004] [Accepted: 12/20/2004] [Indexed: 05/20/2023]
Abstract
A functional genomics project has been initiated to approach the molecular characterization of the main biological and agronomical traits of citrus. As a key part of this project, a citrus EST collection has been generated from 25 cDNA libraries covering different tissues, developmental stages and stress conditions. The collection includes a total of 22,635 high-quality ESTs, grouped in 11,836 putative unigenes, which represent at least one third of the estimated number of genes in the citrus genome. Functional annotation of unigenes which have Arabidopsis orthologues (68% of all unigenes) revealed gene representation in every major functional category, suggesting that a genome-wide EST collection was obtained. A Citrus clementina Hort. ex Tan. cv. Clemenules genomic library, that will contribute to further characterization of relevant genes, has also been constructed. To initiate the analysis of citrus transcriptome, we have developed a cDNA microarray containing 12,672 probes corresponding to 6875 putative unigenes of the collection. Technical characterization of the microarray showed high intra- and inter-array reproducibility, as well as a good range of sensitivity. We have also validated gene expression data achieved with this microarray through an independent technique such as RNA gel blot analysis.
Collapse
Affiliation(s)
- J Forment
- Instituto de Biologíia Molecular y Celular de Plantas (IBMCP), Universidad Politécnica de Valencia, Laboratorio de Genómica, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
del Ara RM, González-Polo RA, Caro A, del Amo E, Palomo L, Hernández E, Soler G, Fuentes JM. Diagnostic performance of arginase activity in colorectal cancer. Clin Exp Med 2002; 2:53-7. [PMID: 12049190 DOI: 10.1007/s102380200007] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Arginase activity was measured in serum and biopsy from healthy individuals and colorectal cancer patients. Arginase activity in tumor samples (87 +/- 7.7 U/g tissue) was significantly higher than in controls (40.7 +/- 3.3 U/g tissue). However, serum arginase activity did not show any significant change in both groups. Finally, the micromethod used to quantify arginase activity in this study is superior to other methods because it has increased sensitivity, requires less sample, and is less time-consuming. Arginase differences are significant, according to the t-test (P<0.05)
Collapse
Affiliation(s)
- Rangel M del Ara
- Departamento de Bioquímica y Biología Molecular, Facultad de Veterinaria, Universidad de Extremadura, Cáceres, Spain
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Adrio JL, Velasco J, Soler G, Rodriguez-Saiz M, Barredo JL, Moreno MA. Extracellular production of biologically active deacetoxycephalosporin C synthase from Streptomyces clavuligerus in Pichia pastoris. Biotechnol Bioeng 2001; 75:485-91. [PMID: 11668449 DOI: 10.1002/bit.10028] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
We have successfully expressed and observed secretion of the Streptomyces clavuligerus deacetoxycephalosporin C synthase (DAOCS) using the Pichia pastoris expression system. Two clones having multiple copies of the expression cassette were selected and used for protein-expression analysis. SDS-PAGE showed efficient expression and secretion of the bacterial recombinant DAOCS. The highest yield (120 microg/mL) was obtained when expression was induced with 2% methanol. Free and immobilized protein were assayed for biological activity and found to expand penicillin N (its natural substrate) and penicillin G to deacetoxycephalosporin C (DAOC) and deacetoxycephalosporin G (DAOG), respectively.
Collapse
Affiliation(s)
- J L Adrio
- Laboratorio de Bioquímica, Departamento de I+D, Antibióticos, S.A.U., Avda. Antibioticos, 59-61, 24009-León, Spain
| | | | | | | | | | | |
Collapse
|
41
|
Abstract
Exposure of cerebellar granule cells to 1-methyl-4-phenylpiridinium (MPP(+)) results in cell death. We have studied the implication of various membrane transporter systems on MPP(+) neurotoxicity, including the dopamine transporter system (DAT) and cationic amino acid transporters (CAT). We have showed a partial protection against MPP(+) toxicity when the dopamine transporter is inhibited by 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]4-(3-phenylpropyl)piperazinedihydrochloride (GBR-12909). However, almost full protection is only achieved by the simultaneous addition of GBR-12909 and cationic amino acids. These results suggest two ways system of MPP(+) entrance into cerebellar granule cells: the DAT with high activity and the CAT with low activity. We also demonstrated that 5,7-dichlorokynurenic acid (MK-801) failed to protect against MPP(+) exposure, evidencing that N-methyl-D-aspartate (NMDA) receptor is not involved in the MPP(+)-induced cell death.
Collapse
MESH Headings
- 1-Methyl-4-phenylpyridinium/metabolism
- 1-Methyl-4-phenylpyridinium/toxicity
- Amino Acid Transport Systems, Basic/drug effects
- Amino Acid Transport Systems, Basic/metabolism
- Amino Acids, Basic/metabolism
- Animals
- Animals, Newborn
- Apoptosis/drug effects
- Apoptosis/physiology
- Carrier Proteins/drug effects
- Carrier Proteins/metabolism
- Cells, Cultured/drug effects
- Cells, Cultured/metabolism
- Cerebellar Cortex/drug effects
- Cerebellar Cortex/metabolism
- Dopamine/metabolism
- Dopamine Plasma Membrane Transport Proteins
- Dopamine Uptake Inhibitors/pharmacology
- Dose-Response Relationship, Drug
- Drug Interactions/physiology
- Excitatory Amino Acid Antagonists/pharmacology
- Female
- Herbicides/metabolism
- Herbicides/toxicity
- MPTP Poisoning/metabolism
- MPTP Poisoning/physiopathology
- Male
- Membrane Glycoproteins
- Membrane Transport Proteins/drug effects
- Membrane Transport Proteins/metabolism
- Nerve Tissue Proteins
- Neurons/drug effects
- Neurons/metabolism
- Neurotoxins/metabolism
- Neurotoxins/toxicity
- Piperazines/pharmacology
- Rats
- Rats, Wistar
- Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors
- Receptors, N-Methyl-D-Aspartate/drug effects
Collapse
Affiliation(s)
- R A González-Polo
- Depto. Bioquímica y Biología Molecular y Genética, Facultad de Veterinaria, Universidad de Extremadura, Cáceres, Spain
| | | | | | | | | | | | | |
Collapse
|
42
|
Sabio G, Mora A, Rangel MA, Quesada A, Marcos CF, Alonso JC, Soler G, Centeno F. Glu-256 is a main structural determinant for oligomerisation of human arginase I. FEBS Lett 2001; 501:161-5. [PMID: 11470277 DOI: 10.1016/s0014-5793(01)02650-3] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
One determinant that could play a role in the quaternary structure of human arginase is the pair of salt links between the strictly conserved residues R255 from one monomer and E256 from every adjacent subunit. In this work, the ionic interaction between monomers was disrupted by expressing a human arginase where Glu-256 had been substituted by Gln. Biochemical analyses of the mutant protein showed that: (i) it shares the wild-type kinetic parameters of the arginine substrate; (ii) E256Q arginase behaves as a monomer by gel filtration; (iii) it is drastically inactivated by dialysis in the presence of EDTA, an inhibitory effect which is reversed by addition of Mn(2+); and (iv) the mutant enzyme loses thermal stability. The lack of oligomerisation for E256Q arginase and the conservation of E256 throughout evolution of the protein family suggest that this residue is involved in the quaternary structure of arginases.
Collapse
Affiliation(s)
- G Sabio
- Departamento de Bioquímica y Biología Molecular, Facultad de Veterinaria, Universidad de Extremadura, Cáceres, Spain
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Mora A, Sabio G, González-Polo RA, Cuenda A, Alessi DR, Alonso JC, Fuentes JM, Soler G, Centeno F. Lithium inhibits caspase 3 activation and dephosphorylation of PKB and GSK3 induced by K+ deprivation in cerebellar granule cells. J Neurochem 2001; 78:199-206. [PMID: 11432986 DOI: 10.1046/j.1471-4159.2001.00410.x] [Citation(s) in RCA: 81] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Lithium protects cerebellar granule cells from apoptosis induced by low potassium, and also from other apoptotic stimuli. However, the precise mechanism by which this occurs is not understood. When cerebellar granule cells were switched to low potassium medium, the activation of caspase 3 was detected within 6 h, suggesting a role of caspase 3 in mediating apoptosis under conditions of low potassium. In the same conditions, lithium (5 mM) inhibited the activation of caspase 3 induced by low potassium. As lithium did not inhibit caspase 3 activity in vitro, these results suggest that this ion inhibits an upstream component that is required for caspase 3 activation. Lithium is known to inhibit a kinase termed glycogen sythase kinase 3 (GSK3), which is implicated in the survival pathway of phosphatidylinositol 3-kinase/protein kinase B (PI3K/PKB). Here we demonstrate that low potassium in the absence of lithium induces the dephosphorylation, and therefore the activation, of GSK3. However, when lithium was present, GSK3 remained phosphorylated at the same level as observed under conditions of high potassium. Low potassium induced the dephosphorylation and inactivation of PKB, whereas when lithium was present PKB was not dephosphorylated. Our results allow us to propose a new hypothesis about the action mechanism of lithium, this ion could inhibit a serine-threonine phosphatase induced by potassium deprivation.
Collapse
Affiliation(s)
- A Mora
- Departamento de Bioquímica y Biología Molecular, Facultad de Veterinaria, Universidad de Extremadura, Avenue Universidad s/n, 10071 Cáceres, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Velasco J, Luis Adrio J, Angel Moreno M, Díez B, Soler G, Barredo JL. Environmentally safe production of 7-aminodeacetoxycephalosporanic acid (7-ADCA) using recombinant strains of Acremonium chrysogenum. Nat Biotechnol 2000; 18:857-61. [PMID: 10932155 DOI: 10.1038/78467] [Citation(s) in RCA: 71] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Medically useful semisynthetic cephalosporins are made from 7-aminodeacetoxycephalosporanic acid (7-ADCA) or 7-aminocephalosporanic acid (7-ACA). Here we describe a new industrially amenable bioprocess for the production of the important intermediate 7-ADCA that can replace the expensive and environmentally unfriendly chemical method classically used. The method is based on the disruption and one-step replacement of the cefEF gene, encoding the bifunctional expandase/hydroxylase activity, of an actual industrial cephalosporin C production strain of Acremonium chrysogenum. Subsequent cloning and expression of the cefE gene from Streptomyces clavuligerus in A. chrysogenum yield recombinant strains producing high titers of deacetoxycephalosporin C (DAOC). Production level of DAOC is nearly equivalent (75-80%) to the total beta-lactams biosynthesized by the parental overproducing strain. DAOC deacylation is carried out by two final enzymatic bioconversions catalyzed by D-amino acid oxidase (DAO) and glutaryl acylase (GLA) yielding 7-ADCA. In contrast to the data reported for recombinant strains of Penicillium chrysogenum expressing ring expansion activity, no detectable contamination with other cephalosporin intermediates occurred.
Collapse
Affiliation(s)
- J Velasco
- Laboratorios de Biotecnología and Bioquímica. Antibióticos S.A., León. Spain
| | | | | | | | | | | |
Collapse
|
45
|
Mora A, del Ara Rangel M, Fuentes JM, Soler G, Centeno F. Implications of the S-shaped domain in the quaternary structure of human arginase. Biochim Biophys Acta 2000; 1476:181-90. [PMID: 10669784 DOI: 10.1016/s0167-4838(99)00256-3] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Arginase I is a homotrimeric protein with a binuclear manganese cluster. At the C-terminus of each monomer, the polypeptide chain forms an unusual S-shaped oligomerization motif where the majority of intermonomer contacts are located [Z.F. Kanyo, L.R. Scolnick, D.E. Ash, D.W. Christianson, Nature 383 (1996) 554-557]. In order to study the implication of this motif in the quaternary structure of human arginase I, we have constructed a truncated arginase lacking the 14 C-terminal amino acids, leaving Arg-308 as the last residue in the sequence. The resulting protein retains its trimeric structure, as determined by gel filtration (molecular mass 94 kDa). The same result was obtained in the presence of high ionic strength (KCl 0.5 M). Both data indicate that neither the S-shaped motif nor Arg-308 are fundamental in keeping the trimeric quaternary structure. Data obtained from intrinsic anisotropy and fluorescence intensity studies allow us to predict that the distance between the two unique tryptophans in the sequence is 2.9 nm in the native arginase and 4.1 nm for the truncated mutant. These distances allow us to assume a different conformational state in the truncated arginase without any change in its quaternary structure, suggesting that the carboxy-terminal motif is not the most prominent domain implicated in the quaternary structure of human arginase. Collisional quenching studies reinforce this possibility, since using I(-) as quenching molecule we were able to distinguish the two tryptophans in the truncated arginase. Moreover, kinetic studies show that the truncated mutant was fully active. In summary, the main conclusion about the structure of the human arginase I, derived from our study, is that the C-terminal S-shaped motif is not basic to the maintenance of the quaternary structure nor to the activity of the protein.
Collapse
Affiliation(s)
- A Mora
- Departamento de Bioquímica y Biología Molecular, Facultad de Veterinaria, Universidad de Extremadura, Av. Universidad s/n, 10071, Cáceres, Spain
| | | | | | | | | |
Collapse
|
46
|
Abstract
Acute treatment with valproate and Li+ was found to protect cultured cerebellar granule cells against apoptosis induced by low K+ (5 mM). Because the protection was unaffected by MK801 (N-methyl-D-aspartate receptor inhibitor), an increase in glutamate release cannot be responsible for the observed neuroprotection. Insulin also protects against low-K+-induced apoptosis of cerebellar granule cells. This protection is totally dependent on LY294002 (a phosphatidylinositol 3-kinase inhibitor). These results suggest a role for phosphatidylinositol 3-kinase in the neuroprotection induced by insulin. Likewise, and in contrast with the results observed with Li+, the protection induced by valproate is also dependent on insulin and LY294002. Moreover, valproate (a branched-chain fatty acid) does not change the plasma membrane microviscosity under physiological conditions. These results suggest that valproate protects against low-K+-induced apoptosis by acting in the phosphatidylinositol 3-kinase/protein kinase B pathway. The protection by Li+ is independent of this transduction pathway.
Collapse
Affiliation(s)
- A Mora
- Departamento de Bioquímica y Biologia Molecular, Facultad de Veterinaria, Universidad de Extremadura, Cáceres, Spain
| | | | | | | | | |
Collapse
|
47
|
Munder M, Eichmann K, Morán JM, Centeno F, Soler G, Modolell M. Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol 1999; 163:3771-7. [PMID: 10490974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
Activated murine macrophages metabolize arginine by two alternative pathways involving the enzymes inducible NO synthase (iNOS) or arginase. The balance between the two enzymes is competitively regulated by Th1 and Th2 T helper cells via their secreted cytokines: Th1 cells induce iNOS, whereas Th2 cells induce arginase. Whereas the role of macrophages expressing iNOS as inflammatory cells is well established, the functional competence of macrophages expressing arginase remains a matter of speculation. Two isoforms of mammalian arginases exist, hepatic arginase I and extrahepatic arginase II. We investigated the regulation of arginase isoforms in murine bone marrow-derived macrophages (BMMPhi) in the context of Th1 and Th2 stimulation. Surprisingly, in the presence of either Th2 cytokines or Th2 cells, we observe a specific induction of the hepatic isoform arginase I in BMMPhi. Induction of arginase I was shown on the mRNA and protein levels and obeyed the recently demonstrated synergism among the Th2 cytokines IL-4 and IL-10. Arginase II was detectable in unstimulated BMMPhi and was not significantly modulated by Th1 or Th2 stimulation. Similar to murine BMMPhi, murine bone marrow-derived dendritic cells, as well as a dendritic cell line, up-regulated arginase I expression and arginase activity upon Th2 stimulation, whereas arginase II was never detected. In addition to revealing the unexpected expression of arginase I in the macrophage/monocyte lineage, these results uncover a further intriguing parallelism between iNOS and arginase: both have a constitutive and an inducible isoform, the latter regulated by the Th1/Th2 balance.
Collapse
Affiliation(s)
- M Munder
- Max-Planck-Institut für Immunbiologie, Freiburg, Germany
| | | | | | | | | | | |
Collapse
|
48
|
Centeno F, Mora A, Fuentes JM, Soler G, Claro E. Partial lithium-associated protection against apoptosis induced by C2-ceramide in cerebellar granule neurons. Neuroreport 1998; 9:4199-203. [PMID: 9926873 DOI: 10.1097/00001756-199812210-00036] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Primary cultures of cerebellar granule neurons, maintained in a serum-containing medium, underwent apoptosis when exposed to C2-ceramide, as assessed by mitochondrial reduction of MTT and intranucleosomal DNA fragmentation. After an 18 h exposure to 50 microM C2-ceramide, cell viability decreased by 25-40%. Addition of lithium together with C2-ceramide resulted in a partial protection of apoptosis, which was maximal at 5 mM lithium (37% protection). When lithium was added 5 h before the apoptotic stimulus the neuroprotective effect of the ion was clearly increased (66% protection). This effect was not due to intracellular inositol depletion or inhibition of NMDA receptors. Our data broaden the nature of apoptotic insults being reversed by lithium, stressing the neuroprotective effects of the ion.
Collapse
Affiliation(s)
- F Centeno
- Departamento de Bioquímica y Biología Molecular, Facultad de Veterinaria, Universidad de Extremadura, Cáceres, Spain
| | | | | | | | | |
Collapse
|
49
|
Grau JJ, Estapé J, Fuster J, Filella X, Visa J, Terés J, Soler G, Albiol S, García-Valdecasas JC, Grande L, Bombí J, Bordas J, Alcobendas F. Randomized trial of adjuvant chemotherapy with mitomycin plus ftorafur versus mitomycin alone in resected locally advanced gastric cancer. J Clin Oncol 1998; 16:1036-9. [PMID: 9508188 DOI: 10.1200/jco.1998.16.3.1036] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
PURPOSE We performed a clinical trial to determine whether postoperative adjuvant chemotherapy with two drugs versus one drug could prolong survival. PATIENTS AND METHODS From 1985 to 1996, 85 patients with completely resected locally advanced gastric cancer were enrolled. The subjects were randomized into two treatment groups, as follows: mitomycin (MMC) 10 to 20 mg/m2 intravenously (i.v.) on day 1 every 6 weeks plus ftorafur (FT) 500 mg/m2/d for 36 consecutive days; or MMC alone, 10 to 20 mg/m2 i.v. every 6 weeks. All courses were repeated four times. RESULTS After a median follow-up duration of 62 months, the overall 5-year survival rates were 67% for the MMC-FT group versus 44% for the MMC group (P = .04). Subgroup analysis to compare survival curves using the method of Mantel-Cox showed survival rates significantly in favor of the MMC-FT group in the subsets of patients with node-negative disease (P = .01) and those whose disease was stage IB or II (P = .008). CONCLUSION Significantly better survival results were observed for MMC-FT versus MMC alone. Subset analysis suggest a strong benefit in patients with node-negative and early-stage resected gastric cancer.
Collapse
Affiliation(s)
- J J Grau
- University of Barcelona, Hospital Clinic, Villarroel, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Soler G, Bastida A, Blanco RM, Fernández-Lafuente R, Guisán JM. Reactivation strategies by unfolding/refolding of chymotrypsin derivatives after inactivation by organic solvents. Biochim Biophys Acta 1997; 1339:167-75. [PMID: 9165111 DOI: 10.1016/s0167-4838(96)00223-3] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Immobilized enzyme derivatives, in organic media at neutral pH and moderate temperatures, should be mainly and perhaps uniquely inactivated by promotion of conformational changes on their 3D structure. Subsequent irreversible inactivation mechanisms (intermolecular aggregations, chemical modifications, thiol-disulfide exchanges) are thus impossible. However, simple reincubation in aqueous medium of enzymes previously inactivated by solvents usually yields significant but slow and incomplete reactivations. Disruption of incorrect protein structures by denaturing agents (urea, guanidine) is proposed as a new strategy to get rapid, complete and technologically feasible reactivations. By using multipoint immobilized chymotrypsin derivatives, we have evaluated the possibility of unfolding and further refolding of native (non-inactivated) derivatives by different denaturing conditions. After unfolding in 8 M guanidine, derivatives were quickly and completely refolded up to 100% of catalytic activity in 10 minutes. Besides, successive cycles of unfolding and refolding could be exactly reproduced. Finally we checked the possibility to reactivate chymotrypsin derivatives inactivated by dioxane. Simple reincubations in aqueous media yielded a poor reactivation even after 24 hours. However, unfolding in 8 M guanidine enabled complete reactivation in less than 2 hours. From this point of view, by working under 'chemically inert conditions' (moderate pH and temperatures), fully dispersed covalently immobilized enzyme derivatives seem to behave as almost everlasting catalysts despite the very deleterious effect of organic media.
Collapse
Affiliation(s)
- G Soler
- Departamento de Biocatálisis, Instituto de Catálisis, CSIC, Campus Universidad Autónoma, Madrid, Spain
| | | | | | | | | |
Collapse
|